Stockreport

U.S. FDA declines to approve Revance's frown-line treatment [Reuters]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF drug to treat moderate to severe frown lines, sending its shares plunging 29%. The company said the FDA pointed to "deficiencies" related to the regulator's inspection [Read more]